Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients

Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients

N Areepium,1 D Panomvana,1 P Rungwanonchai,1 S Sathaporn,2 N Voravud3 1Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 2Department of Surgery, Phramongkutklao Hospital, Bangkok, 3Department of Medicine, Faculty of Medicine, Chulalongkorn Univer...

Full description

Bibliographic Details
Main Authors:	Areepium N, Panomvana D, Rungwanonchai P, Sathaporn S, Voravud N
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-08-01
Series:	Breast Cancer : Targets and Therapy
Online Access:	http://www.dovepress.com/effects-of-cyp2d6-and-ugt2b7-polymorphisms-on-pharmacokinetics-of-tamo-a14130

Similar Items

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
by: Charoenchokthavee W, et al.
Published: (2017-04-01)

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
by: Charoenchokthavee W, et al.
Published: (2016-08-01)

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
by: Sirachainan E, et al.
Published: (2012-10-01)

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.
by: Alicia Romero-Lorca, et al.
Published: (2015-01-01)

Correction: Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.
by: PLOS ONE Staff
Published: (2015-01-01)

The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children
by: Pavlovic D, et al.
Published: (2020-01-01)

Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen
by: Chamnanphon M, et al.
Published: (2013-05-01)

Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen
by: Sensorn I, et al.
Published: (2013-08-01)

Effect of CYP3A5 Genotypes on the Pharmacokinetics of Carbamazepine when used as Monotherapy or Co-Administered with Phenytoin, Phenobarbital or Valproic Acid in Thai Patients
by: Duangchit Panomvana, et al.
Published: (2013-09-01)

The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1
by: Din, J., et al.

The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
by: Din, J, et al.

The Association among Metabolites of Tobacco Carcinogen NNK, Genetic Polymorphisms of CYP2A13 and UGT2B7, and Urothelial Carcinoma
by: Hsiu-Yuan Yang, et al.
Published: (2009)

CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset
by: Per Damkier, et al.
Published: (2017-08-01)

Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms
by: Pithukpakorn M, et al.
Published: (2014-12-01)

Association between ESR1, ESR2, HER2, UGT1A4, and UGT2B7 polymorphisms and breast Cancer in Jordan: a case-control study
by: Laith N. AL-Eitan, et al.
Published: (2019-12-01)

The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis
by: Lu J, et al.
Published: (2017-11-01)

Physiologically-based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance
by: Kristin eDickschen, et al.
Published: (2012-05-01)

Drug serum levels and genetic polymorphisms of UGT1A3, UGT1A4, UGT2B7 and HLA involved in lamotrigine hypersensitivity.
by: Chun-Yi Wu, et al.
Published: (2010)

ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen
by: Sensorn I, et al.
Published: (2016-04-01)

Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients.
by: Aleksandra Markiewicz, et al.
Published: (2013-01-01)

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
by: Jennifer D. Brooks, et al.
Published: (2018-12-01)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
by: A. B. Sanchez-Spitman, et al.
Published: (2021-01-01)

The Impact of Combination Tamoxifen and CYP2D6 Inhibitory Antidepressants on The Treatment of Breast Cancer
by: Yi-Ching Wang, et al.
Published: (2013)

Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients’ Population
by: Kristina Bojanic, et al.
Published: (2020-05-01)

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
by: Roberta Ferraldeschi, et al.
Published: (2010-04-01)

The implication of the polymorphisms of COX-1, UGT1A6, and CYP2C9 among cardiovascular disease patients treated with aspirin
by: Abdul Jalil, N.J, et al.
Published: (2015)

A comprehensive overview of common polymorphic variants that cause missense mutations in human CYPs and UGTs
by: Xiaolin Cao, et al.
Published: (2019-03-01)

The Effects of CYP2D6*10 Polymorphisms on Tamoxifen Metabolism, Bone Mineral Density and Clinical Outcomes in Taiwanese Breast Cancer Patients and In vitro study of Tamoxifen and its Active Metabolites on Osteoclast.
by: Wu, Shang-Luen, et al.
Published: (2013)

Effects of CYP2C9 and CYP2C19 Polymorphisms on the Population Pharmacokinetics of Phenytoin in Taiwanese Patients with Epilepsy
by: 洪靚娟
Published: (2002)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
by: Clara Inkyung Lee, et al.
Published: (2020-12-01)

The Implication of the Polymorphisms of COX-1, UGT1A6, and CYP2C9 among Cardiovascular Disease Patients Treated with Aspirin
by: Ali, O, et al.
Published: (2015)

The polymorphisms of UGT1A7 and UGT1A10 among Taiwan lung cancer patients.
by: LEE, YU-CHING, et al.
Published: (2005)

CYP2D6-GENOTYPING IN THE ASSESSMENT OF THE EFFECTIVENESS OF THERAPY WITH TAMOXIFEN IN PATIENTS WITH ADVANCED HORMONE RECEPTOR-POSITIVE BREAST CANCER
by: L. N. Lyubchenko, et al.
Published: (2017-12-01)

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
by: Chung H, et al.
Published: (2015-05-01)

CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study
by: Wickramage I, et al.
Published: (2017-03-01)

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.
by: Danny W K Lum, et al.
Published: (2013-01-01)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
by: Werner Schroth, et al.
Published: (2017-08-01)

Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.
by: Ana Fernández-Santander, et al.
Published: (2013-01-01)

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
by: Sukasem C, et al.
Published: (2013-08-01)

Genetic variation in the 3'-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2 and UGT2B7: potential effect on regulation by microRNA and pharmacogenomics relevance
by: Marelize eSwart, et al.
Published: (2014-06-01)